Being chosen by big pharma doesn’t ensure alliance success, nor does simply having great science. In this paper, Oaklin’s Nick Palmer describes the key behaviours needed to ensure your partnership goes the
distance.
Alliance Potential: Becoming the target of choice in big pharma’s portfolio.
